cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14498257
title: Efficacy and safety of Chinese patent medicine (Kang-ai injection) as an adjuvant in the treatment of patients with hepatocellular carcinoma: a meta-analysis

description: Kang-ai injection (KAI) is an authorized herbal medicine used in cancer treatment. However, its clinical efficacy in hepatocellular carcinoma (HCC) has not been investigated thoroughly. To systematically evaluate the efficacy and safety of KAI in patients with HCC. The Web of Science, PubMed, Cochrane Library, EMBASE, CBM, CNKI, VIP and Wanfang databases were systematically searched (date range: inception to December 2020) using the key terms ‘Kang-ai injection’ and ‘hepatocellular carcinoma’. The current analysis included controlled clinical trials that compared the efficacy and safety of the combination of KAI and conventional treatment (CT) with CT alone for HCC. The current study estimated the pooled risk ratio (RR) with 95% confidence intervals (CI). Data pertaining to 35 trials with 2501 HCC patients were analysed. The results revealed that the combination of KAI and CT was associated with significantly superior objective response rate (RR = 1.57, 95% CI = 1.43–1.73), disease control rate (RR = 1.18, 95% CI = 1.10–1.26), and quality of life (RR = 2.40, 95% CI = 1.79–3.23), compared to CT alone. The administration of KAI significantly alleviated most of the adverse effects caused by CT, including nausea and vomiting, liver damage, peripheral neurotoxicity, fever, abdominal pain, alopecia, increased bilirubin levels, leukopoenia, and reduction in haemoglobin levels (<i>p</i> &lt; 0.05, for all). The current meta-analysis indicates that a combination of CT and KAI could be more effective in improving the clinical efficacy of the treatment of HCC, compared to CT alone.
DOI: 10.6084/m9.figshare.14498257.v1
title: Efficacy and safety of Chinese patent medicine (Kang-ai injection) as an adjuvant in the treatment of patients with hepatocellular carcinoma: a meta-analysis

description: Kang-ai injection (KAI) is an authorized herbal medicine used in cancer treatment. However, its clinical efficacy in hepatocellular carcinoma (HCC) has not been investigated thoroughly. To systematically evaluate the efficacy and safety of KAI in patients with HCC. The Web of Science, PubMed, Cochrane Library, EMBASE, CBM, CNKI, VIP and Wanfang databases were systematically searched (date range: inception to December 2020) using the key terms ‘Kang-ai injection’ and ‘hepatocellular carcinoma’. The current analysis included controlled clinical trials that compared the efficacy and safety of the combination of KAI and conventional treatment (CT) with CT alone for HCC. The current study estimated the pooled risk ratio (RR) with 95% confidence intervals (CI). Data pertaining to 35 trials with 2501 HCC patients were analysed. The results revealed that the combination of KAI and CT was associated with significantly superior objective response rate (RR = 1.57, 95% CI = 1.43–1.73), disease control rate (RR = 1.18, 95% CI = 1.10–1.26), and quality of life (RR = 2.40, 95% CI = 1.79–3.23), compared to CT alone. The administration of KAI significantly alleviated most of the adverse effects caused by CT, including nausea and vomiting, liver damage, peripheral neurotoxicity, fever, abdominal pain, alopecia, increased bilirubin levels, leukopoenia, and reduction in haemoglobin levels (<i>p</i> &lt; 0.05, for all). The current meta-analysis indicates that a combination of CT and KAI could be more effective in improving the clinical efficacy of the treatment of HCC, compared to CT alone.
DOI: 10.6084/m9.figshare.16584152
title: Network pharmacology-based analysis in determining the mechanisms of Huoxin pill in protecting against myocardial infarction

description: Huoxin pill (HXP) is a commonly used TCM prescription for treatment of cardiovascular diseases. However, its mechanism in protecting against myocardial infarction (MI) remains unknown. We performed a network pharmacology analysis to explore the bioactive ingredients, therapeutic effects, and mechanisms of HXP in protecting against MI. HPLC was used to identify major bioactive compounds, and overlap with MI target genes were visualised. 10-Week old C57BL/6 mice were randomly assigned as: Sham-operated control, MI + Phosphate buffered saline (PBS), and MI + HXP (3 mg/mL and 9 mg/mL) treatment groups, received oral gavage administration once every two-days starting from 1-week prior to MI, and subsequently MI models were established for one-week before sacrifice. AKT1, VEGFA, TNF and RELA were identified as core target proteins among eighty-five candidate bioactive compounds identified in HXP with overlapping MI-related genes. HXP protection against MI was mainly via regulation of inflammatory pathways, notably TNF signalling pathway. Mouse models of MI and cardiac myoblasts demonstrated that HXP improved MI-induced injury via improving regulation of inflammatory response. Stellasterol, deoxycholic acid, kaempferol, and quercetin are important active compounds contained in HXP with anti-inflammatory properties in the therapeutic treatment of MI. Due to the straightforward nature and effectiveness of taking oral HXP medications, our findings provide a theoretical basis for the clinical application of HXP in treating patients with angina or myocardial ischaemia. Future research into the combination of surgical procedures or medications that restore blood flow together with HXP as supportive medication would be worthwhile.
DOI: 10.6084/m9.figshare.16584152.v1
title: Network pharmacology-based analysis in determining the mechanisms of Huoxin pill in protecting against myocardial infarction

description: Huoxin pill (HXP) is a commonly used TCM prescription for treatment of cardiovascular diseases. However, its mechanism in protecting against myocardial infarction (MI) remains unknown. We performed a network pharmacology analysis to explore the bioactive ingredients, therapeutic effects, and mechanisms of HXP in protecting against MI. HPLC was used to identify major bioactive compounds, and overlap with MI target genes were visualised. 10-Week old C57BL/6 mice were randomly assigned as: Sham-operated control, MI + Phosphate buffered saline (PBS), and MI + HXP (3 mg/mL and 9 mg/mL) treatment groups, received oral gavage administration once every two-days starting from 1-week prior to MI, and subsequently MI models were established for one-week before sacrifice. AKT1, VEGFA, TNF and RELA were identified as core target proteins among eighty-five candidate bioactive compounds identified in HXP with overlapping MI-related genes. HXP protection against MI was mainly via regulation of inflammatory pathways, notably TNF signalling pathway. Mouse models of MI and cardiac myoblasts demonstrated that HXP improved MI-induced injury via improving regulation of inflammatory response. Stellasterol, deoxycholic acid, kaempferol, and quercetin are important active compounds contained in HXP with anti-inflammatory properties in the therapeutic treatment of MI. Due to the straightforward nature and effectiveness of taking oral HXP medications, our findings provide a theoretical basis for the clinical application of HXP in treating patients with angina or myocardial ischaemia. Future research into the combination of surgical procedures or medications that restore blood flow together with HXP as supportive medication would be worthwhile.
DOI: 10.5281/zenodo.10849356
title: Data for the AGU journal submission 2023RS007925R

description: This file contains data required to reproduce plots in "Design and Characterization of the Engineering Model of the Spectrometer Onboard
LuSEE-Night" by Emi Tamura et al, which has been accepted for publication in Radio Science.
DOI: 10.6084/m9.figshare.20173050.v2
title: Comparative study on the gastrointestinal- and immune- regulation functions of Hedysari Radix Praeparata Cum Melle and Astragali Radix Praeparata cum Melle in rats with spleen-qi deficiency, based on fuzzy matter-element analysis

description: Hedysari Radix Praeparata Cum Melle (HRPCM) and Astragali Radix Praeparata Cum Melle (ARPCM) are used interchangeably in clinics to treat spleen-qi deficiency (SQD) symptom mainly including gastrointestinal dysfunction and decreased immunity, which has unknown differences in efficacy. To investigate the differences between HRPCM and ARPCM on intervening gastrointestinal- and immune-function with SQD syndrome. After the SQD model was established, the Sprague–Dawley (SD) rats were randomly divided into nine groups (<i>n</i> = 10): normal; model; Bu-Zhong-Yi-Qi Pills; 18.9, 12.6 and 6.3 g/kg dose groups of HRPCM and ARPCM. Gastrointestinal function including d-xylose, gastrin, amylase vasoactive intestinal peptide, motilin, pepsin, H<sup>+</sup>/K<sup>+</sup>-ATPase, Na<sup>+</sup>/K<sup>+</sup>-ATPase, sodium-glucose cotransporter 1 (SGLT1), glucose transporter 2 (GLUT2) and immune function including spleen and thymus index, blood routine, interleukin (IL)-2, IL-6, interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), immunoglobulin (Ig) M, IgA, IgG and delayed-type hypersensitivity (DTH) were detected. Finally, the efficacy differences were analysed comprehensively by the fuzzy matter-element method. In regulating immune, the doses differences in efficacy between HRPCM and ARPCM showed in the high-dose (18.9 g/kg), but there were no differences in the middle- and low- dose (12.6 and 6.3 g/kg); the efficacy differences were primarily reflected in levels of IL-6, IFN-γ, TNF-α and IgM in serum, and the mRNA expression of IL-6 and IFN-γ in the spleen. In regulating gastrointestinal, the efficacy differences were primarily reflected in the levels of D-xylose, MTL, and GAS in serum, and the mRNA and protein expression of SGLT1 and GLUT2 in jejunum and ileum. HRPCM is more effective than ARPCM on regulating gastrointestinal function and immune function with SQD syndrome. Therefore, we propose that HRPCM should be mainly used to treat SQD syndrome in the future.
DOI: 10.5287/ora-7ryz4gerb
title: Eosinophil scRNAseq data from patients with asthma before and after mepolizumab treatment

description: scRNAseq of eosinophils from patients with asthma at the baseline and 1-month after 1st dose of mepolizumab injection was performed using plate-based system (Smart-Seq2). It consists of 1x count matrix (filtered) and 1x sample information sheet in a RData format.
DOI: 10.6084/m9.figshare.17197957
title: Platelet response to aspirin in UK and Irish pregnancy cohorts: a genome-wide approach

description: A multi-center prospective cross-sectional and genome-wide association study (GWAS) recruited pregnant women taking low dose aspirin. Objectives were to (i) develop pregnancy-specific 95% reference intervals for a range of laboratory based platelet function tests (PFTs); (ii) select an optimal and acceptable PFT that reflected aspirin’s COX-1 inhibition in women with confirmed aspirin adherence in pregnancy; and (iii) identify genomic variants that may influence pregnant women’s platelet response to aspirin. The study included two independent cohorts of pregnant women. A range of PFTs and matched phenotyping with urinary 11-dehydrothromboxane B<sub>2</sub> (11DTXB2) and nuclear magnetic resonance (NMR) spectroscopy detection of urinary salicyluric acid as a measure of aspirin adherence were performed. Genome-wide data was acquired from the UK Biobank Axiom® (Thermo Fisher Scientific). 11DTXB2 in combination with adherence testing with NMR salicyluric acid was an accurate and acceptable testing strategy for detecting biochemical aspirin responsiveness in pregnant women, with the provision of relevant reference ranges. GWAS meta-analysis found no significant single nucleotide polymorphisms in association with response to aspirin in pregnancy. Further evaluation in relation to effective dosing of aspirin in pregnancy and optimizing the benefits to specific subgroups should now be a priority for future research.
DOI: 10.15482/usda.adc/25164449
title: Long-read sequencing data from pure cultures of <i>Escherichia coli</i> O157:H7 and ground beef inoculated with <i>E. coli</i> O157:H7

description: Foodborne pathogens are a significant cause of illness and infection with Shiga toxin-producing <i>Escherichia coli</i> (STEC) has the potential to produce life-threatening complications. The current methods to identify STEC in meat involve culture-based, molecular, and proteomic assays and take at least four days to complete. This time could be reduced by using long-read whole genome sequencing to identify foodborne pathogens. Therefore, the goal of this project was to evaluate using long-read sequencing to detect STEC in ground beef. The objectives of the project included: establishing optimal sequencing parameters, determining the limit of detection of all STEC virulence genes of interest in pure cultures and spiked ground beef, and evaluating selective sequencing to enhance STEC detection in ground beef. Sequencing libraries were run on Oxford Nanopore Technologies’ MinION sequencer. Optimal sequencing output was obtained using the default parameters in MinKNOW, except for setting the minimum read length to 1 kb. All genes of interest (<i>eae</i>, <i>stx1</i>, <i>stx2</i>, <i>fliC</i>, <i>wzx</i>, <i>wzy</i>, <i>rrsC</i>) were detected in DNA extracted from STEC pure cultures within 1 hour of sequencing, and 30X coverage was obtained within 2 hours. All virulence genes were confidently detected in STEC DNA quantities as low as 12.5 ng. In STEC inoculated ground beef, software-controlled selective sequencing improved virulence gene detection; however, several virulence genes were not detected due to high bovine DNA concentrations in the samples. Growth enrichment of inoculated meat samples in mTSB resulted in a 100-fold increase in virulence gene detection as compared to the unenriched samples. The results of this project suggest that further development of long-read sequencing protocols may result in a faster, less labor-intensive method to detect STEC in ground beef. The sequencing data from this project has been uploaded.
DOI: 10.15482/usda.adc/25164449.v1
title: Long-read sequencing data from pure cultures of <i>Escherichia coli</i> O157:H7 and ground beef inoculated with <i>E. coli</i> O157:H7

description: Foodborne pathogens are a significant cause of illness and infection with Shiga toxin-producing <i>Escherichia coli</i> (STEC) has the potential to produce life-threatening complications. The current methods to identify STEC in meat involve culture-based, molecular, and proteomic assays and take at least four days to complete. This time could be reduced by using long-read whole genome sequencing to identify foodborne pathogens. Therefore, the goal of this project was to evaluate using long-read sequencing to detect STEC in ground beef. The objectives of the project included: establishing optimal sequencing parameters, determining the limit of detection of all STEC virulence genes of interest in pure cultures and spiked ground beef, and evaluating selective sequencing to enhance STEC detection in ground beef. Sequencing libraries were run on Oxford Nanopore Technologies’ MinION sequencer. Optimal sequencing output was obtained using the default parameters in MinKNOW, except for setting the minimum read length to 1 kb. All genes of interest (<i>eae</i>, <i>stx1</i>, <i>stx2</i>, <i>fliC</i>, <i>wzx</i>, <i>wzy</i>, <i>rrsC</i>) were detected in DNA extracted from STEC pure cultures within 1 hour of sequencing, and 30X coverage was obtained within 2 hours. All virulence genes were confidently detected in STEC DNA quantities as low as 12.5 ng. In STEC inoculated ground beef, software-controlled selective sequencing improved virulence gene detection; however, several virulence genes were not detected due to high bovine DNA concentrations in the samples. Growth enrichment of inoculated meat samples in mTSB resulted in a 100-fold increase in virulence gene detection as compared to the unenriched samples. The results of this project suggest that further development of long-read sequencing protocols may result in a faster, less labor-intensive method to detect STEC in ground beef. The sequencing data from this project has been uploaded.
DOI: 10.6084/m9.figshare.25444714
title: Supplementary Material for: Die translationale Revolution bei der atopischen Dermatitis: Der Paradigmenwechsel von der Pathogenese zur Behandlung

description:  Die atopische Dermatitis (AD) ist die häufigste entzündliche Haut­erkrankung und gilt als komplexe und heterogene Erkrankung. Kürzlich wurden verschiedene AD-Phänotypen beschrieben, die nach dem Alter des Patienten zu Beginn, dem ethnischen Hintergrund, der Krankheitsdauer und anderen Krankheitsmerkmalen definiert wurden und der Notwendigkeit eines personalisierten Behandlungsansatzes zugrunde liegen. Jüngste Fortschritte beim Verständnis der AD-Pathogenese führten zu einer echten translationalen Revolution und zu einer exponentiellen Erweiterung der therapeutischen Pipeline. Die Untersuchung von Biomarkern in klinischen Studien zu neuen Behandlungen trägt dazu bei, die Rolle jedes Zytokins und Immunwegs bei der AD zu klären und wird es ermöglichen, den einzigartigen immunologischen Fingerabdruck jeder AD-Untergruppe zu adressieren. Die personalisierte Medizin wird das ultimative Ziel dieser gezielten translationalen Forschung sein. In dieser Übersichtsarbeit diskutieren wir die Veränderungen in den Konzepten sowohl der Pathogenese als auch des Behandlungsansatzes für AD, heben die wissenschaftliche Begründung für jede zielgerichtete Behandlung hervor und berichten über die neuesten klinischen Daten zur Wirksamkeit.
DOI: 10.6084/m9.figshare.25444714.v2
title: Supplementary Material for: Die translationale Revolution bei der atopischen Dermatitis: Der Paradigmenwechsel von der Pathogenese zur Behandlung

description:  Die atopische Dermatitis (AD) ist die häufigste entzündliche Haut­erkrankung und gilt als komplexe und heterogene Erkrankung. Kürzlich wurden verschiedene AD-Phänotypen beschrieben, die nach dem Alter des Patienten zu Beginn, dem ethnischen Hintergrund, der Krankheitsdauer und anderen Krankheitsmerkmalen definiert wurden und der Notwendigkeit eines personalisierten Behandlungsansatzes zugrunde liegen. Jüngste Fortschritte beim Verständnis der AD-Pathogenese führten zu einer echten translationalen Revolution und zu einer exponentiellen Erweiterung der therapeutischen Pipeline. Die Untersuchung von Biomarkern in klinischen Studien zu neuen Behandlungen trägt dazu bei, die Rolle jedes Zytokins und Immunwegs bei der AD zu klären und wird es ermöglichen, den einzigartigen immunologischen Fingerabdruck jeder AD-Untergruppe zu adressieren. Die personalisierte Medizin wird das ultimative Ziel dieser gezielten translationalen Forschung sein. In dieser Übersichtsarbeit diskutieren wir die Veränderungen in den Konzepten sowohl der Pathogenese als auch des Behandlungsansatzes für AD, heben die wissenschaftliche Begründung für jede zielgerichtete Behandlung hervor und berichten über die neuesten klinischen Daten zur Wirksamkeit.
DOI: 10.6084/m9.figshare.25444714.v1
title: Supplementary Material for: Die translationale Revolution bei der atopischen Dermatitis: Der Paradigmenwechsel von der Pathogenese zur Behandlung

description:  Die atopische Dermatitis (AD) ist die häufigste entzündliche Haut­erkrankung und gilt als komplexe und heterogene Erkrankung. Kürzlich wurden verschiedene AD-Phänotypen beschrieben, die nach dem Alter des Patienten zu Beginn, dem ethnischen Hintergrund, der Krankheitsdauer und anderen Krankheitsmerkmalen definiert wurden und der Notwendigkeit eines personalisierten Behandlungsansatzes zugrunde liegen. Jüngste Fortschritte beim Verständnis der AD-Pathogenese führten zu einer echten translationalen Revolution und zu einer exponentiellen Erweiterung der therapeutischen Pipeline. Die Untersuchung von Biomarkern in klinischen Studien zu neuen Behandlungen trägt dazu bei, die Rolle jedes Zytokins und Immunwegs bei der AD zu klären und wird es ermöglichen, den einzigartigen immunologischen Fingerabdruck jeder AD-Untergruppe zu adressieren. Die personalisierte Medizin wird das ultimative Ziel dieser gezielten translationalen Forschung sein. In dieser Übersichtsarbeit diskutieren wir die Veränderungen in den Konzepten sowohl der Pathogenese als auch des Behandlungsansatzes für AD, heben die wissenschaftliche Begründung für jede zielgerichtete Behandlung hervor und berichten über die neuesten klinischen Daten zur Wirksamkeit.
DOI: 10.14473/csda/g7cb19/m07vbe
title: TI_V0703.pdf

description: Technická informace
DOI: 10.14473/csda/g7cb19/ioxkis
title: K_V0703.pdf

description: Karty
DOI: 10.14473/csda/g7cb19/zirr3e
title: OM_V0703.pdf

description: Ostatní materiály
DOI: 10.14473/csda/g7cb19/zdmroc
title: D_V0703.pdf

description: Dotazník
DOI: 10.14473/csda/g7cb19/k8kovv
title: Nesstar_NS_DataFile_0703.tab

description: Data
DOI: 10.14473/csda/g7cb19/b5jphk
title: PR10_V0703.pdf

description: Politická kultura v ČR. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/mbszc3
title: PR06_V0703.pdf

description: Důvěra k stranickým představitelům. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/2m5r6f
title: PR08_V0703.pdf

description: Postoje k aférám v politickém a veřejném životě. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/vbno6n
title: PR11_V0703.pdf

description: Stranické preference a volební model v březnu 2007. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/q4sqri
title: PR05_V0703.pdf

description: Důvěra k ústavním institucím a spokojenost s politickou situací v březnu 2007. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/clfpvm
title: PR07_V0703.pdf

description: Důvěra k některým institucím veřejného života. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/jnt9es
title: PR01_V0703.pdf

description: Hodnocení informací v médiích. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/drscht
title: PR03_V0703.pdf

description: Co je pro nás morálně přijatelné a co nikoli? Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/4zq4bg
title: PR09_V0703.pdf

description: Kdy by měl politik odstoupit ze své funkce? Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19
title: Naše společnost 2007 - březen

description: Kontinuální měsíční výzkum provedl výzkumný tým CVVM Sociologického ústavu AV ČR v rámci pravidelného měsíčního výzkumného projektu. Jsou při něm zjišťovány postoje a názory občanů. Výzkum provedl výzkumný tým CVVM Sociologického ústavu AV ČR v rámci výzkumu. "Naše společnost 2007". Sběr dat provedla tazatelská síť CVVM.
DOI: 10.14473/csda/g7cb19/auzf86
title: PR04_V0703.pdf

description: Diskuze občanů o politických tématech, představy o vlivech na rozhodování politiků. Tisková zpráva CVVM.
DOI: 10.14473/csda/g7cb19/kinbnw
title: PR02_V0703.pdf

description: Jak jsou na tom Češi s tolerancí? Tisková zpráva CVVM.
DOI: 10.14272/fkshoqtwuwcwtg-uhfffaoysa-n/chmo0000596.1
title: distortionless enhancement with polarization transfer (DEPT) ((4-acetyl-3-acetyloxyphenyl) acetate)
title: InChI=1S/C12H12O5/c1-7(13)11-5-4-10(16-8(2)14)6-12(11)17-9(3)15/h4-6H,1-3H3

description: dataset for distortionless enhancement with polarization transfer (DEPT)
DOI: 10.14272/fkshoqtwuwcwtg-uhfffaoysa-n/chmo0000596
title: distortionless enhancement with polarization transfer (DEPT) ((4-acetyl-3-acetyloxyphenyl) acetate)
title: InChI=1S/C12H12O5/c1-7(13)11-5-4-10(16-8(2)14)6-12(11)17-9(3)15/h4-6H,1-3H3

description: dataset for distortionless enhancement with polarization transfer (DEPT)
DOI: 10.14272/fkshoqtwuwcwtg-uhfffaoysa-n/chmo0000604
title: heteronuclear single quantum coherence (HSQC) ((4-acetyl-3-acetyloxyphenyl) acetate)
title: InChI=1S/C12H12O5/c1-7(13)11-5-4-10(16-8(2)14)6-12(11)17-9(3)15/h4-6H,1-3H3

description: dataset for heteronuclear single quantum coherence (HSQC)
DOI: 10.14272/fkshoqtwuwcwtg-uhfffaoysa-n/chmo0000470
title: mass spectrometry (MS) ((4-acetyl-3-acetyloxyphenyl) acetate)
title: InChI=1S/C12H12O5/c1-7(13)11-5-4-10(16-8(2)14)6-12(11)17-9(3)15/h4-6H,1-3H3

description: dataset for mass spectrometry (MS)
 
 MS (EI, 70 eV, 70 °C), m/z (%): 236 (6) [M]+, 194 (35), 152 (93), 137 (100). HRMS–EI (C12H12O5) (m/z): [M]+ Calcd 236.0679; Found 236.0681.